Find a Clinical Trial
Filter
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
CABG HRV via WHOOP
Coronary artery disease
All genders
20+
Recruiting now
Department of Anesthesiology + Perioperative Medicine
Discovery
Glaucoma
All genders
No minimum age
Recruiting now
Department of Ophthalmology
Feasibility of a new method for non-invasive monitoring of low-grade bladder cancer
Bladder cancer
All genders
18-90
Recruiting now
Department of Urology
Home and Bedside Visual Fields
Vision health
All genders
15-80
Recruiting now
Department of Ophthalmology
ETS3
Vision impairment
All genders
3-9
Recruiting now
Department of Ophthalmology
Relationship between Protein intake and ICU Skeletal muscle weakness
Arm or leg weakness
All genders
18-50
Recruiting now
Department of Anesthesiology + Perioperative Medicine
Infant Vision Health and Prenatal Drug Exposure
Vision health
All genders
0-5
Recruiting now
Department of Obstetrics + Gynecology